Compare Bristol-Myers Squibb Co (BMY) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Cloudflare Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Cloudflare Inc trades at $283.67 (market cap $100.00B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| BMY | NET | |
|---|---|---|
Market Cap | $116.30B | $100.00B |
Sector | Health | Technology |
52-Week High | $62.37 | $281.69 |
52-Week Low | $42.60 | $160.16 |
Enterprise Value | $152.24B | $99.36B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Cloudflare (NET) trades at $269.45, up 0.39% on the day, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth is strong, reaching $2.17 billion in 2025, but profitability remains a challenge with a net income margin of -3.72%. Recent news highlights strategic AI partnerships and product launches, including a research pilot with OpenAI and the introduction of Precursor for bot management.
The outlook for NET is cautiously optimistic, driven by AI infrastructure demand and cybersecurity tailwinds, but high valuation multiples and persistent losses pose risks. Analyst consensus is strongly bullish with a 72.5% buy rating, though the current price exceeds the average target of $257.43. Investors should weigh growth potential against profitability concerns and competitive pressures in the cloud sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
